On May 21, 2020 RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, reported that Dr. Johanna Bendell, Director of the Drug Development Unit at Sarah Cannon Research Center in Nashville, will present an oral abstract related to the RGX-202 program at the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Scientific Program (Press release, Rgenix, MAY 21, 2020, RGENIX To Present RGX-202 Phase I Data at 2020 ASCO (Free ASCO Whitepaper) Virtual Scientific Program [SID1234558431]). The meeting is scheduled to take place May 29 – 31, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of Rgenix’s presentation are as follows:

Event: 2020 ASCO (Free ASCO Whitepaper) Virtual Scientific Program

Date: May 29, 2020

Time: 8:00 AM EDT (available for download)

Description: Abstract #3504, "Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors."